In this paper, an objective technique for estimating the tropical cyclone （TC） precipitation from station observations is proposed. Based on a comparison between the Original Objective Method （OOM） and the Expert ...In this paper, an objective technique for estimating the tropical cyclone （TC） precipitation from station observations is proposed. Based on a comparison between the Original Objective Method （OOM） and the Expert Subjective Method （ESM）, the Objective Synoptic Analysis Technique （OSAT） for partitioning TC precipitation was developed by analyzing the western North Pacific （WNP） TC historical track and the daily precipitation datasets. Being an objective way of the ESM, OSAT overcomes the main problems in OOM, by changing two fixed parameters in OOM, the thresholds for the distance of the absolute TC precipitation （D0） and the TC size （D1）, into variable parameters.Case verification for OSAT was also carried out by applying CMORPH （Climate Prediction Center MORPHing technique） daily precipitation measurements, which is NOAA＇s combined satellite precipitation measurement system. This indicates that OSAT is capable of distinguishing simultaneous TC precipitation rain-belts from those associated with different TCs or with middle-latitude weather systems.展开更多
Background:Effective therapeutic options are limited for patients with advanced esophageal squamous cell carcinoma(ESCC).The incorporation of an immune checkpoint inhibitor and a molecular anti-angiogenic agent into t...Background:Effective therapeutic options are limited for patients with advanced esophageal squamous cell carcinoma(ESCC).The incorporation of an immune checkpoint inhibitor and a molecular anti-angiogenic agent into the commonly adopted chemotherapy may produce synergistic effects.Therefore,we aimed to investigate the efficacy and safety of camrelizumab plus apatinib combined with chemotherapy as the first-line treatment of advanced ESCC.Methods:In this single-arm prospective phase II trial,patients with unresectable locally advanced or recurrent/metastatic ESCC received camrelizumab 200 mg,liposomal paclitaxel 150 mg/m2,and nedaplatin 50 mg/m2 on day 1,and apatinib 250 mg on days 1-14.The treatments were repeated every 14 days for up to 9 cycles,followed by maintenance therapy with camrelizumab and apatinib.The primary endpoint was objective response rate(ORR)according to the Response Evaluation Criteria in Solid Tumors(version 1.1).Secondary endpoints included disease control rate(DCR),progression-free survival(PFS),overall survival(OS),and safety.Results:We enrolled 30 patients between August 7,2018 and February 23,2019.The median follow-up was 24.98 months(95%confidence interval[CI]:23.05-26.16 months).The centrally assessed ORR was 80.0%(95%CI:61.4%-92.3%),with a median duration of response of 9.77 months(range:1.54 to 24.82+months).The DCR reached 96.7%(95%CI:82.8%-99.9%).The median PFS was 6.85 months(95%CI:4.46-14.20 months),and the median OS was 19.43 months(95%CI:9.93 months–not reached).The most common grade 3-4 treatmentrelated adverse events(AEs)were leukopenia(83.3%),neutropenia(60.0%),and increased aspartate aminotransferase level(26.7%).Treatment-related serious AEs included febrile neutropenia,leukopenia,and anorexia in one patient(3.3%),and single cases of increased blood bilirubin level(3.3%)and toxic epidermal necrolysis(3.3%).No treatment-related deaths occurred.Conclusions:Camrelizumab plus apatinib combined with liposomal paclitaxel and nedaplatin as first-line treatment demonstrated feas展开更多
文摘In this paper, an objective technique for estimating the tropical cyclone （TC） precipitation from station observations is proposed. Based on a comparison between the Original Objective Method （OOM） and the Expert Subjective Method （ESM）, the Objective Synoptic Analysis Technique （OSAT） for partitioning TC precipitation was developed by analyzing the western North Pacific （WNP） TC historical track and the daily precipitation datasets. Being an objective way of the ESM, OSAT overcomes the main problems in OOM, by changing two fixed parameters in OOM, the thresholds for the distance of the absolute TC precipitation （D0） and the TC size （D1）, into variable parameters.Case verification for OSAT was also carried out by applying CMORPH （Climate Prediction Center MORPHing technique） daily precipitation measurements, which is NOAA＇s combined satellite precipitation measurement system. This indicates that OSAT is capable of distinguishing simultaneous TC precipitation rain-belts from those associated with different TCs or with middle-latitude weather systems.
基金This study was supported by the Chinese Society of Clinical Oncology(CSCO)-Hengrui Oncology Research Fund(No.Y-HR2018-364)。
文摘Background:Effective therapeutic options are limited for patients with advanced esophageal squamous cell carcinoma(ESCC).The incorporation of an immune checkpoint inhibitor and a molecular anti-angiogenic agent into the commonly adopted chemotherapy may produce synergistic effects.Therefore,we aimed to investigate the efficacy and safety of camrelizumab plus apatinib combined with chemotherapy as the first-line treatment of advanced ESCC.Methods:In this single-arm prospective phase II trial,patients with unresectable locally advanced or recurrent/metastatic ESCC received camrelizumab 200 mg,liposomal paclitaxel 150 mg/m2,and nedaplatin 50 mg/m2 on day 1,and apatinib 250 mg on days 1-14.The treatments were repeated every 14 days for up to 9 cycles,followed by maintenance therapy with camrelizumab and apatinib.The primary endpoint was objective response rate(ORR)according to the Response Evaluation Criteria in Solid Tumors(version 1.1).Secondary endpoints included disease control rate(DCR),progression-free survival(PFS),overall survival(OS),and safety.Results:We enrolled 30 patients between August 7,2018 and February 23,2019.The median follow-up was 24.98 months(95%confidence interval[CI]:23.05-26.16 months).The centrally assessed ORR was 80.0%(95%CI:61.4%-92.3%),with a median duration of response of 9.77 months(range:1.54 to 24.82+months).The DCR reached 96.7%(95%CI:82.8%-99.9%).The median PFS was 6.85 months(95%CI:4.46-14.20 months),and the median OS was 19.43 months(95%CI:9.93 months–not reached).The most common grade 3-4 treatmentrelated adverse events(AEs)were leukopenia(83.3%),neutropenia(60.0%),and increased aspartate aminotransferase level(26.7%).Treatment-related serious AEs included febrile neutropenia,leukopenia,and anorexia in one patient(3.3%),and single cases of increased blood bilirubin level(3.3%)and toxic epidermal necrolysis(3.3%).No treatment-related deaths occurred.Conclusions:Camrelizumab plus apatinib combined with liposomal paclitaxel and nedaplatin as first-line treatment demonstrated feas
